Cencora, Inc. $COR Shares Bought by SG Americas Securities LLC

Key Points

• SG Americas Securities LLC increased its stake in Cencora by 1,750.8% in Q4, buying 302,281 shares to hold 319,546 shares worth about $107.9 million (≈0.16% of the company).
• Cencora agreed to buy EyeSouth Partners’ retina business for about $1.1 billion to expand higher‑margin ophthalmology services, but the deal — alongside the CFO’s planned retirement and a high debt‑to‑equity ratio (3.62) — raises integration and leverage concerns.
• Cencora beat EPS estimates for the quarter ($4.08 vs. $4.04) while revenue slightly missed; the company pays a quarterly dividend of $0.60 (0.7% yield) and holds a "Moderate Buy" analyst consensus with an average target of $403.17.

SG Americas Securities LLC grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 1,750.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 319,546 shares of the company's stock after purchasing an additional 302,281 shares during the quarter. SG Americas Securities LLC owned about 0.16% of Cencora worth $107,927,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in COR. IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the 3rd quarter worth $30,000. Vermillion & White Wealth Management Group LLC grew its stake in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company's stock worth $31,000 after buying an additional 43 shares during the last quarter. Cloud Capital Management LLC acquired a new position in Cencora during the 3rd quarter valued at about $31,000. Caitlin John LLC acquired a new position in Cencora during the 3rd quarter valued at about $31,000. Finally, Westside Investment Management Inc. raised its stake in Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company's stock valued at $33,000 after buying an additional 70 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Down 1.9%

Cencora stock opened at $320.68 on Tuesday. The business's 50-day simple moving average is $354.50 and its two-hundred day simple moving average is $340.44. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market cap of $62.38 billion, a PE ratio of 38.54, a PEG ratio of 1.52 and a beta of 0.68. Cencora, Inc. has a fifty-two week low of $265.59 and a fifty-two week high of $377.54.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. During the same period last year, the business posted $3.73 earnings per share. The company's revenue for the quarter was up 5.5% compared to the same quarter last year. Equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora's dividend payout ratio (DPR) is currently 28.85%.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora agreed to buy the retina business of EyeSouth Partners for about $1.1 billion, expanding its Retina Consultants of America platform and adding specialized ophthalmology services that can drive higher-margin, recurring revenue and cross‑sell opportunities within its clinical and distribution businesses. Cencora to buy retina business of EyeSouth Partners for $1.1 billion — Reuters
• Neutral Sentiment: Cencora is included in actively managed ETF lineups (mentioned in a MarketBeat piece on active ETFs), which could modestly support demand from funds that favor active strategies but is unlikely to materially change near‑term fundamentals. Active ETFs Surge Past Passive, and These Are in the Lead — MarketBeat
• Neutral Sentiment: Multiple industry outlets and deal roundups covered the EyeSouth sale and other sector M&A activity — reinforcing that consolidation in specialty care remains active but not necessarily changing Cencora’s near‑term revenue guidance. Olympus Partners to sell EyeSouth’s retina business for $1.1b — PEHub
• Negative Sentiment: CFO retirement and a planned leadership change this summer raise questions about near‑term capital allocation and execution on growth plans; combined with the $1.1B deal, investors may be concerned about leverage and integration risk given Cencora’s relatively high debt levels. Cencora CFO Retirement Puts Capital Allocation And Growth Plans In Focus — Yahoo Finance

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.38% of the company's stock.

Analysts Set New Price Targets

COR has been the subject of several recent analyst reports. Morgan Stanley set a $380.00 price target on Cencora in a report on Tuesday, March 17th. Wall Street Zen downgraded shares of Cencora from a "buy" rating to a "hold" rating in a report on Friday, November 28th. Barclays increased their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an "overweight" rating in a research report on Friday, February 13th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 10th. Finally, Bank of America dropped their target price on shares of Cencora from $380.00 to $360.00 and set a "neutral" rating on the stock in a research report on Monday, January 5th. Twelve equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus price target of $403.17.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.